NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

But you didn't elaborate further on why the subtype of GBM which has the most significant genetic mutations responds the best to DCVax.

Let me tell you why. The subtype of GBM which has more significant genetic mutations can trigger more intense immune response and more cancer cells can be eliminated by activated t-cells before tumor-associated macrophages take the control. The subtype that has less genetic mutations will take time for strong anti-tumor response to build up and hence gives TAMs more time to catch up.

Once TAMs are depleted by CSF1R inhibitors, we have a cure. The combination trial that NWBO is about to file IND will be tumor-agnostic type for tough cancers with immunosuppressive characteristics dominated by TAMs.